Wall Street analyst estimates for Thermo Fisher Scientific Inc. (TMO): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-10-28 | $6.40 | ||
| 2026-07-23 | $6.03 | $5.72 | +5.4% |
| 2026-04-23 | $5.44 | $5.25 | +3.6% |
| 2026-01-29 | $6.57 | $6.45 | +1.9% |
| 2025-10-22 | $5.79 | $5.50 | +5.3% |
| 2025-07-23 | $5.36 | $5.23 | +2.5% |
| 2025-04-23 | $5.15 | $5.10 | +1.0% |
| 2025-01-30 | $6.10 | $5.94 | +2.7% |
Valuation Ratios
| P/E Ratio | 36.71 |
| Price / Book | 4.81 |
| EV / EBITDA | 24.37 |
| Dividend Yield | 0.27% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $18.27B | $20.92B | $24.36B | $25.54B | $32.22B | $39.21B | $44.91B | $42.86B | $42.88B | $44.56B |
| Cost of Revenue | $9.69B | $11.24B | $13.37B | $14.20B | $16.19B | $19.58B | $25.90B | $25.66B | $25.15B | $27.78B |
| Gross Profit | $8.58B | $9.68B | $10.99B | $11.34B | $16.03B | $19.63B | $19.01B | $17.19B | $17.73B | $16.78B |
| Research & Development | $754.8M | $888.0M | $967.0M | $1.00B | $1.18B | $1.41B | $1.47B | $1.34B | $1.39B | $1.40B |
| Selling, General & Admin | $4.87B | $5.41B | $6.03B | $6.06B | $6.95B | $7.91B | $9.02B | $8.41B | $8.68B | $7.27B |
| Operating Expenses | $5.72B | $6.41B | $7.12B | $7.08B | $8.13B | $9.32B | $10.49B | $9.75B | $10.07B | $8.67B |
| Operating Income | $2.86B | $3.27B | $3.87B | $4.26B | $7.90B | $10.32B | $8.53B | $7.45B | $7.66B | $8.11B |
| EBITDA | $4.25B | $5.05B | $6.20B | $7.02B | $10.11B | $11.97B | $11.94B | $11.20B | $11.80B | $11.47B |
| Interest Expense | $469.6M | $592.0M | $667.0M | $676.0M | $553.0M | $536.0M | $726.0M | $1.49B | $1.65B | $1.42B |
| Pre-tax Income | $2.02B | $2.43B | $3.26B | $4.07B | $7.23B | $8.84B | $7.66B | $6.24B | $7.00B | $7.27B |
| Income Tax | -$1.4M | $201.0M | $324.0M | $374.0M | $850.0M | $1.11B | $703.0M | $284.0M | $657.0M | $547.0M |
| Net Income | $2.02B | $2.23B | $2.94B | $3.70B | $6.38B | $7.72B | $6.95B | $6.00B | $6.33B | $6.74B |
| EPS | $5.12 | $5.64 | $7.31 | $9.24 | $16.10 | $19.61 | $17.73 | $15.53 | $16.58 | $17.77 |
| EPS (Diluted) | $5.09 | $5.59 | $7.24 | $9.17 | $15.98 | $19.46 | $17.64 | $15.45 | $16.53 | $17.74 |
| Shares Outstanding (Diluted) | $397.4M | $398.0M | $406.0M | $403.0M | $399.0M | $397.0M | $394.0M | $388.0M | $383.0M | $377.0M |
Price
| Price | $658.32 |
| Market Cap | $244.6B |
| Exchange | NYSE |
| Country | US |
Related companies: A · ABT · AMGN · AZN · DHR · IQV · ISRG
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of TMO: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks